SLN
Silence Therapeutics Plc
$6.93
+$0.17(+2.51%)
67
Overall
40
Value
90
Tech
71
Quality
Market Cap
$314.03M
Volume
382.92K
52W Range
$4.19 - $8.40
Target Price
$31.20
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Mar | 2024 Sep | 2024 Dec | 2025 Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | $244.0K | $5.5M | $12.4M | $17.3M | $25.4M | $15.7M | $1.1M | $33.8M | $142.0K | ||
| Total Revenue | -- | $244.0K | $5.5M | $12.4M | $17.5M | $25.4M | $15.7M | $1.1M | $33.8M | $142.0K | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | $3.8M | $7.5M | $10.9M | $10.3M | $2.8M | $2.8M | $9.2M | $54.0K | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | $244.0K | $1.7M | $5.0M | $6.6M | $15.1M | $12.9M | $-1.6M | $24.6M | $88.0K | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $20.6M | $23.0M | $34.2M | $50.8M | $55.2M | $64.7M | $13.3M | $20.9M | $73.6M | $28.5M | ||
| Research & Development | $9.7M | $13.3M | $20.2M | $30.8M | $35.6M | $44.0M | $6.6M | $15.3M | $53.3M | $20.8M | ||
| Research Expense | -- | -- | -- | -- | $35.6M | $44.0M | $6.6M | $15.3M | $53.3M | $20.8M | ||
| Selling, General & Administrative | $10.8M | $9.6M | $14.0M | $20.0M | $19.6M | $20.6M | $6.6M | $5.6M | $20.3M | $7.7M | ||
| General & Administrative Expenses | $10.8M | $9.6M | $14.0M | $20.0M | $19.6M | $20.6M | $6.6M | $5.6M | $20.3M | $7.7M | ||
| Salaries & Wages | -- | -- | -- | -- | -- | $13.1M | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | -- | $-66.0K | -- | $498.0K | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | -- | $-66.0K | -- | $498.0K | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | $-2.0K | -- | $36.0K | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | $3.4M | -- | -- | $1.3M | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-20.6M | $-22.7M | $-32.5M | $-45.8M | $-48.6M | $-49.6M | $-371.0K | $-22.5M | $-49.0M | $-28.4M | ||
| EBITDA | $-20.5M | $-22.4M | $-35.5M | -- | $-46.8M | $-47.7M | $2.6M | $-21.6M | $-44.5M | $-28.4M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | $33.0K | $16.0K | $8.0K | $47.0K | $2.2M | $13.0K | $8.6M | $74.0K | -- | ||
| Intinc | $39.0K | $27.0K | $129.0K | $10.0K | $226.0K | $1.4M | $804.0K | $981.0K | $4.0M | -- | ||
| Net Non-Operating Interest Income/Expense | $-39.0K | $6.0K | $-113.0K | $-2.0K | $179.0K | $-706.0K | $791.0K | $-7.6M | $4.0M | -- | ||
| Gain on Sale of Securities | -- | -- | $-3.7M | $-44.0K | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | -- | -- | $-3.7M | $-44.0K | -- | -- | $-3.2M | -- | -- | $-3.6M | ||
| Other Special Charges | -- | -- | -- | -- | -- | -- | $3.2M | -- | -- | $3.6M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-20.5M | $-22.8M | $-36.0M | $-45.9M | $-47.3M | $-48.2M | $2.4M | $-21.6M | $-45.0M | $-28.5M | ||
| Pre-Tax Income | $-20.5M | $-22.9M | $-36.0M | $-45.9M | $-47.4M | $-50.3M | $2.4M | $-30.2M | $-45.1M | $-28.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-2.1M | $-3.3M | $-3.5M | $-6.4M | $-6.9M | $-7.0M | $244.0K | $-3.1M | $-9.8M | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-18.4M | $-19.6M | $-32.5M | $-39.4M | $-40.5M | $-43.3M | $2.2M | $-27.0M | $-35.2M | $-28.5M | ||
| Net Income (Continuing Operations) | $-18.4M | $-19.6M | $-32.5M | $-39.4M | $-40.5M | $-43.3M | $2.2M | $-27.0M | $-35.2M | $-28.5M | ||
| Net Income (Discontinued Operations) | $-18.4M | $-19.6M | $-32.5M | $-39.4M | $-40.5M | $-43.3M | $2.2M | $-27.0M | $-35.2M | $-28.5M | ||
| Net Income (Common Stockholders) | $-18.4M | $-19.6M | $-32.5M | $-39.4M | $-40.5M | $-43.3M | $2.2M | $-27.0M | $-35.2M | $-28.5M | ||
| Normalized Income | $-22.6M | $-26.2M | $-39.5M | $-52.3M | $-54.2M | $-57.4M | $2.4M | $-33.3M | $-54.9M | $-28.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-20.6M | $-23.0M | $-38.0M | $-58.2M | $66.1M | $75.0M | $16.1M | $23.7M | $82.9M | $28.6M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $70.3M | $75.1M | $81.8M | -- | $96.6M | $111.3M | $131.9M | $47.1M | $138.8M | $141.7M | ||
| Average Shares Outstanding (Diluted) | $70.3M | $75.1M | $81.8M | -- | $96.6M | $111.3M | $131.9M | $47.1M | $138.8M | $141.7M | ||
| Shares Outstanding | $36.7M | $36.7M | $36.7M | $36.7M | $36.7M | $36.7M | $46.6M | $47.2M | $141.7M | $141.7M | ||
| Basic EPS | $-0.26 | $-0.26 | $-0.40 | -- | $-0.42 | $-0.39 | $-0.02 | $0.57 | $-0.25 | $-0.20 | ||
| Basic EPS (Continuing Operations) | $-0.26 | $-0.26 | $-0.40 | -- | $-0.42 | $-0.39 | $-0.02 | $0.57 | $-0.25 | $-0.20 | ||
| Diluted EPS | $-0.26 | $-0.26 | $-0.40 | -- | $-0.42 | $-0.39 | $-0.02 | $0.57 | $-0.25 | $-0.20 | ||
| Diluted EPS (Continuing Operations) | $-0.26 | $-0.26 | $-0.40 | -- | $-0.42 | $-0.39 | $-0.02 | $0.57 | $-0.25 | $-0.20 | ||
| OTHER METRICS | ||||||||||||
| Loss And Loss Adjustment Expected Incurred | -- | -- | -- | -- | -- | $2.1M | -- | -- | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | $10.9M | $10.3M | $2.8M | $2.8M | $9.2M | $54.0K | ||
| Other Gand A | $10.8M | $9.6M | $14.0M | $20.0M | $19.6M | $20.6M | $6.6M | $5.6M | $20.3M | $7.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLN | $6.93 | +2.5% | 382.92K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Silence Therapeutics Plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW